Walgreens adds virtual coverage navigation, Medicare GLP-1 Bridge support, and pharmacist follow-up calls as GLP-1 discontinuation remains high.
|Articles|November 2, 2020
Pharmacy Times: Week of November 2 Lineup
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.
Advertisement
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week, including:
- A video interview with Ned Milenkovich, principal and co-chair of the Health Care Law practice group at Much Shelist, about how federal and state law may affect vaccine administration in accordance with recent declarations by the US Department of Health and Human Services (HHS) authorizing pharmacists to administer vaccines to children during the coronavirus disease 2019 (COVID-19) pandemic and to order and administer an eventual COVID-19 vaccine once it’s available.
- On Wednesday, Pharmacy Times will publish a clinical review of new migraine drugs that target the triptan contraindication population.
Advertisement
Related to this article
Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association discusses pharmacists’ role in diabetes and CKD care from ASN Kidney Week 2026
A helpful guide for pharmacists if teas, supplements, or cultural foods are part of a patient's regular routine.
Pharmacists can support effective cancer pain treatment by starting constipation prevention with opioid therapy and reassessing bowel function before symptoms become a barrier to care.
Six-year NATALEE data show adjuvant ribociclib (Kisqali) plus endocrine therapy improves overall survival in high-risk HR+/HER2- early breast cancer, with pharmacist-led monitoring.
Jai Radhakrishnan, MD, discusses why IgG4-related kidney disease is often missed and what MITIGATE subgroup data presented at ASN Kidney Week 2026 show
Real-world data from ASN Kidney Week show GLP-1 RA users with CKD and obesity had lower rates of kidney failure, death, and heart failure exacerbation.
The FDA expanded approval of talazoparib plus enzalutamide to HRR-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer following a significant radiographic PFS benefit in TALAPRO-3.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Cystatin C and the Future of Kidney Function Assessment
2
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
3
Walgreens Adds Pharmacist Outreach, Coverage Help for GLP-1s
4
GLP-1 RAs, Finerenone, and CKD: Key Data From Kidney Week 2026
5